Home›Trial›NCT07179380
NCT07179380Phase 3RECRUITING

Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Study Summary

The primary objective of this study is to evaluate the effect of 24-weeks of once daily treatment with TPIP versus placebo on exercise capacity in adults with PH-ILD.

Conditions
Pulmonary HypertensionInterstitial Lung Disease
Interventions / Drugs
Treprostinil Palmitil Inhalation PowderPlacebo
View on ClinicalTrials.gov ↗
Sponsor
INSM
Insmed Incorporated
Rare Disease
D39/100
Study Details
Enrollment344 participants
Primary Completion—
Lead SponsorInsmed Incorporated
Data Retrieved2026-04-11 04:17:39.580859+00:00
What This Trial Means for Biotech Investors
Trial Phase Context

Phase 3 trials are pivotal studies with large patient populations (hundreds to thousands) designed to prove efficacy and safety for FDA submission. A successful Phase 3 readout is typically the last major hurdle before a New Drug Application (NDA) or BLA filing.

Status & Expected Data

Currently recruiting: the trial is enrolling patients. A data readout is not expected until after enrollment closes and the follow-up period is complete.

Enrolled: 344 participants
Sponsor Catalyst Profile

Insmed Incorporated (INSM) is the sponsoring company for this trial. BiotechSign currently grades this company D (39/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

INSM Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.